NBT 588
Latest Information Update: 28 Apr 2026
At a glance
- Originator NewBio Therapeutics
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for research development in Unspecified in China (Parenteral)
- 23 Mar 2022 Early research in Unspecified in China (Parenteral) before March 2022 (NewBio Therapeutics pipeline, March 2022)